Literature DB >> 24157035

Clinical outcomes of Pneumocystis carinii pneumonia in adult liver transplant recipients.

Y-I Choi1, S Hwang, G-C Park, J-M Namgoong, D-H Jung, G-W Song, T-Y Ha, D-B Moon, K-H Kim, C-S Ahn, S-G Lee.   

Abstract

PURPOSE: Pneumocystis carinii pneumonia (PCP) is an opportunistic infection associated with morbidity and mortality in solid-organ transplant recipients. We retrospectively assessed the characteristics and outcomes of liver transplant (OLT) recipients with PCP compared with those of patients with severe non-P carinii pneumonia (non-PCP) who required intensive care with mechanical ventilation.
METHODS: During the 2-year period between January 2008 and December 2009, 43 adult OLT recipients had severe pneumonia requiring mechanical ventilation; of these, 8 (19%) had PCP. During this period, routine antibiotic prophylaxis was administered for the first 6 months after OLT.
RESULTS: The median period from OLT to development of PCP was 9.5 months (range, 1-67); the 1-year incidence was 0.9%. The 6 and 6 to 12-month incidences of non-PCP were 4.2% and 0.3%, respectively, and those of PCP were 0.3% and 0.6%, respectively. Four of 8 patients (50%) in the PCP group had a recent history of a rejection episode. PCP was associated with a higher incidence of prior antirejection treatment. There were no significant differences between PCP and non-PCP groups in age, gender, preoperative Model for End-stage Liver Disease score, primary diagnosis, graft type, and total number of rejection episodes.
CONCLUSIONS: These results indicate that the risk of PCP in OLT recipients is closely related to strong immunosuppressive treatment for acute cellular rejection episodes, suggesting the importance of PCP prophylaxis in these patients. Because most patients developed PCP at around 1 year, it may be advisable to prolong routine post-OLT PCP prophylaxis for 12 months, especially among patients receiving antirejection treatment.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24157035     DOI: 10.1016/j.transproceed.2013.08.074

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Serious fungal infections in Korea.

Authors:  K Huh; Y E Ha; D W Denning; K R Peck
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-02-04       Impact factor: 3.267

2.  Pneumocystis pneumonia in liver transplant recipients.

Authors:  Xian-Liang Li; Zi-Xi Liu; Zhen-Jia Liu; Han Li; Benjamin Wilde; Oliver Witzke; Man Qi; Wen-Li Xu; Qiang He; Ji-Qiao Zhu
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

3.  Diagnosis and treatment of pulmonary cavity after liver transplantation.

Authors:  Yongxiang Xia; Haoming Zhou; Feipeng Zhu; Wei Zhang; Chen Wu; Ling Lu
Journal:  Ann Transl Med       Date:  2017-08

4.  Infectious Complications After Liver Transplantation.

Authors:  Maria Del Pilar Hernandez; Paul Martin; Jacques Simkins
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-11

Review 5.  Approach to the Solid Organ Transplant Patient with Suspected Fungal Infection.

Authors:  Judith A Anesi; John W Baddley
Journal:  Infect Dis Clin North Am       Date:  2015-12-28       Impact factor: 5.982

Review 6.  Pneumocystis Pneumonia in Solid-Organ Transplant Recipients.

Authors:  Xavier Iriart; Marine Le Bouar; Nassim Kamar; Antoine Berry
Journal:  J Fungi (Basel)       Date:  2015-09-28

7.  The Long-Acting Echinocandin, Rezafungin, Prevents Pneumocystis Pneumonia and Eliminates Pneumocystis from the Lungs in Prophylaxis and Murine Treatment Models.

Authors:  Melanie T Cushion; Alan Ashbaugh
Journal:  J Fungi (Basel)       Date:  2021-09-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.